Business
Telo Genomics Announces Investor Relations Agreement and Option Grants
Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB:...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Announces Investor Relations Agreement and Option GrantsToronto, Ontario--(Newsfile Corp. - March 15, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce that it has engaged Tracey Kidd (\"Kidd\") to perform services related to investor relations activities for the Company, as defined in accordance with the polices of the TSX Venture Exchange (\"TSXV\") and applicable securities laws.Pursuant to an engagement agreement entered into with Kidd on March 15, 2022 (the \"Engagement Agreement\"), Kidd will receive a cash monthly fee of $7,500 over a period of twelve months. The Company has granted Kidd 120,000 stock options, with each option exercisable into one common share at an exercise price of $0.335 per share. 30,000 options will vest three months following the date of the Engagement Agreement, and 30,000 options shall vest on each of September 15th, 2022, December 15th, 2022, and March 15th, 2023. All vested options shall be eligible for exercise until the earlier of (i) 30 days following termination of the Agreement, and (ii) two years from the date of grant. In addition, in connection with Dr. Ron McGlennen's appointment as a director of the Company, as previously announced on February 3, 2022, he has been granted 250,000 options with a term of 5 years and an exercise price of $0.335 per common share pursuant to TELO's approved stock option plan. The stock option grants and the Engagement Agreement are subject to the approval of the TSX Venture Exchange.The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsi...